Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives $45.71 Consensus PT from Analysts

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $45.7143.

A number of research firms have commented on ZBIO. Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Morgan Stanley boosted their price objective on shares of Zenas BioPharma from $22.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Wedbush restated an “outperform” rating and set a $45.00 target price on shares of Zenas BioPharma in a report on Friday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd.

Zenas BioPharma Trading Up 3.3%

ZBIO opened at $32.55 on Thursday. The company has a quick ratio of 9.93, a current ratio of 9.93 and a debt-to-equity ratio of 1.57. The stock’s fifty day moving average is $31.62 and its two-hundred day moving average is $24.96. The company has a market capitalization of $2.12 billion, a P/E ratio of -3.62 and a beta of -1.04. Zenas BioPharma has a 52 week low of $13.50 and a 52 week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The business had revenue of $1.00 million during the quarter, compared to analyst estimates of $15.00 million. Analysts forecast that Zenas BioPharma will post -5.81 earnings per share for the current year.

Institutional Trading of Zenas BioPharma

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Zenas BioPharma in the second quarter valued at approximately $68,176,000. Wellington Management Group LLP raised its holdings in shares of Zenas BioPharma by 27.9% during the 2nd quarter. Wellington Management Group LLP now owns 1,593,819 shares of the company’s stock worth $40,451,000 after acquiring an additional 347,766 shares during the period. Polar Capital Holdings Plc purchased a new stake in shares of Zenas BioPharma during the 4th quarter valued at approximately $38,402,000. Bank of America Corp DE acquired a new position in Zenas BioPharma in the second quarter valued at about $31,247,000. Finally, EcoR1 Capital LLC acquired a new position in Zenas BioPharma during the fourth quarter worth $28,667,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.

Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus.